• Press Release/Announcement
  • Published February 2015

FDA requires label warnings to prohibit sharing of multi-dose diabetes pen devices among patients.

The practice of using multi-dose insulin pens, meant for single patient use only, among multiple patients has been linked to health care–associated infections. This announcement outlines federal labeling requirements to raise awareness of the risks associated with this practice to prevent misuse of the devices.

Back to Top